Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)

Atherosclerosis

Volumn 205, Issue 2, 2009, Pages 522-527

  Holme, Ingar ^a   Strandberg, Timo E ^b   Faergeman, Ole ^c   Kastelein, John J P ^d   Olsson, Anders G ^e   Tikkanen, Matti J ^f   Larsen, Mogens Lytken ^c   Lindahl, Christina ^g   Pedersen, Terje R ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OULU   (Finland)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g Pfizer Sweden   (Sweden)

Author keywords

Apolipoproteins; Congestive heart failure; Lipoproteins; Risk prediction; Statin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG DOSE INCREASE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CORONARY DISEASE; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS; SIMVASTATIN;

EID: 67650908132     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.01.023     Document Type: Article

References (18)

1. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 20 (2003) 2007-2018
2. Velagaleti R.S., and Vasan R.S. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem?. Cardiol Clin 25 4 (2007) 487-495
3. Khush K.K., Waters D.D., Bittner V., et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115 5 (2007) 576-583
4. Strandberg T., Tikkanen M., and Holme I. Group ftIS High-dose atorvastatin as compared to usual simvastatin treatment is associated with less congestive heart failure in secondary prevention. Eur Heart J 29 Suppl. (2008) 767
5. Sever P.S., Poulter N.R., Dahlof B., et al. The anglo-scandinavian cardiac outcomes trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 29 4 (2008) 499-508
6. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 22 (2007) 2248-2261
7. Horwich T.B., Hamilton M.A., Maclellan W.R., and Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 4 (2002) 216-224
8. Dhingra R., Sesso H.D., Kenchaiah S., and Gaziano J.M. Differential effects of lipids on the risk of heart failure and coronary heart disease: the physicians' health study. Am Heart J 155 5 (2008) 869-875
9. Iwaoka M., Obata J.E., Abe M., et al. Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure. J Card Fail 13 4 (2007) 247-253
10. Ingelsson E., Arnlov J., Sundstrom J., et al. Novel metabolic risk factors for heart failure. J Am Coll Cardiol 46 11 (2005) 2054-2060
11. Sueta C.A., Massing M.W., Chowdhury M., Biggs D.P., and Simpson Jr. R.J. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. J Card Fail 9 1 (2003) 36-41
12. Holme I., Cater NB., Faergeman O., et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL). Ann Med (2008) 1-9
13. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 19 (2005) 2437-2445
14. Hansson L., Hedner T., and Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. prospective randomized open blinded end-point. Blood Press 1 2 (1992) 113-119
15. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 6 (1972) 499-502
16. Marcovina S.M., Albers J.J., Henderson L.O., and Hannon W.H. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 39 5 (1993) 773-781
17. Marcovina S.M., Albers J.J., Kennedy H., et al. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 40 4 (1994) 586-592
18. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 7 (2007) 776-785